Skip to main content

Table 1 Patient demographics

From: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Patient demographics

 

Age (yr)

 

Median

9.8

Range

5-13.5

Weight (kg)

 

Median

30.5

Range

14.3-62.7

Gender (n)

 

Male intact

3

Castrated male

23

Female spayed

14

Tumor type (n)

 

Soft tissue sarcoma

7

Thyroid carcinoma

7

Anal sac adenocarcinoma

7

Nasal carcinoma

5

Squamous cell carcinoma

4

OSA (lung metastasis)

3

Primary pulmonary carcinoma

3

Billiary carcinoma

1

Poorly differentiated carcinoma (neck and jaw)

1

Salivary gland adenocarcinoma

1

Mediastinal carcinoma

1

Prior therapy (n)

 

Yes

15

No

25